[Immediate cardiac toxicity of rubidazone. A case reversible by isoproterenol].
It is reported the first observation of cardiogenic shock without delay, in a leukemic patient during a first injection of Rubidazone (22050 RP) which is recognized so far, as one of the least cardiotoxic anthracyclines. It has been concluded: --anthracyclines, beside the risk of a progressive cardiomyopathy which is related to the dose and very well known, can induce immediate cardiac injuries, which cannot be predicted yet; --the perfect myocardial protector is still to be discovered; --in this case, beta-adrenergic stimulators appeared to be able to control the cardiotoxic effect of Rubidazone; --the last fact could be considered in the decision to maintain the treatment when such an injury occurs during a chemotherapy or when it seems absolutely necessary to use such a drug.
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008875:Middle Aged; D012770:Shock, Cardiogenic / Q000139:chemically induced* / Q000517:prevention & control
D000903:Antibiotics, Antineoplastic; D007545:Isoproterenol; C002205:zorubicin; D003630:Daunorubicin
Toxicité cardiaque immédiate à la rubidazone. Un cas réversible sous isoprotérénol.